209-218
Mini Review
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials
G. Nasti, A. Ottaiano, M. Berretta, P. Delrio and F. Izzo, et al.
219-227
Original Article
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase
Andrea Réti, Éva Pap, Vilmos Adleff, András Jeney and Judit Kralovánszky, et al.
229-235
Original Article
Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
Su Jin Lee, Jeeyun Lee, Ho Yeong Lim, Won Ki Kang and Chel Hun Choi, et al.
237-243
Original Article
Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines
Yoshitsugu Horio, Hirotaka Osada, Junichi Shimizu, Shizu Ogawa and Toyoaki Hida, et al.
245-254
Original Article
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents
Kosalaram Goteti, C. Edwin Garner, Lucas Utley, Jing Dai and Susan Ashwell, et al.
255-264
Original Article
Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells
Aleksandar Radujkovic, Stefan Fruehauf, W. Jens Zeller, Anthony D. Ho and Julian Topaly
265-267
Original Article
Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
Daniel P. Greene, James Stuart Ferriss and Amir A. Jazaeri
269-276
Original Article
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Kaname Yamamoto, Masatoshi Shirane and Yoriko Yamashita, et al.
277-285
Original Article
Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo
Xiaolei Ye, Wu Zhou, Yongqi Li, Yihua Sun and Yihua Zhang, et al.
287-294
Original Article
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
Steven J. Cohen, Mark M. Zalupski, Manuel R. Modiano, Paul Conkling and Yehuda Z. Patt, et al.
295-301
Original Article
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
Trine Zeeberg Buch-Hansen, Lise Bentzen, Steinbjoern Hansen, Morten Hoeyer and Niels Viggo Jensen, et al.
303-314
Original Article
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats
Karol L. Thompson, Barry A. Rosenzweig, Jun Zhang, Alan D. Knapton and Ronald Honchel, et al.
315-323
Original Article
Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
Valentina K. Todorova, Yihong Kaufmann, Leah J. Hennings and V. Suzanne Klimberg
325-331
Original Article
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Kelley A. Sookraj, Wilbur B. Bowne, Victor Adler, Ehsan Sarafraz-Yazdi and Josef Michl, et al.
333-343
Original Article
Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Yukimoto Ishii, Shigeru Suzuki, Yasuo Takahashi, Tadatoshi Takayama and Satoshi Asai
345-356
Original Article
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
Christopher J. Sweeney, Chris Takimoto, Leslie Wood, Jennifer M. Porter and William G. Tracewell, et al.
357-371
Original Article
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen and George D. Demetri, et al.
373-380
Original Article
Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer
Sun Jin Sym, Min-Hee Ryu, Hye Jin Kang, Sung Sook Lee and Heung-Moon Chang, et al.
381-388
Original Article
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
Yun Jung Choi, Jin Kyung Rho, Byung-suk Jeon, Su Jin Choi and Su Cheol Park, et al.
389-394
Original Article
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
F. Caponigro, D. Lorusso, G. Fornari, C. Barone and M. Merlano, et al.
395-403
Clinical Trial Report
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
Emmanuel Mitry, Pascal Hammel, Gaël Deplanque, Françoise Mornex and Philippe Levy, et al.
405-407
Short Communication
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
N. A. Helsby, W. Y. Lo, P. Thompson and G. R. Laking
409-412
Short Communication
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy
Anilkumar Katta, Mark J. Fesler, Alan Tan, Giao Vuong and John M. Richart